Search

​Nucala is indicated as add-on maintenance treatment for adult patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.

​Rybrevant in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) exon 20 insertion mutations.

OPZELURA (ruxolitinib (as ruxolitinib phosphate)) cream 1.5% is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with conventional topical prescription therapies (topical corticosteroids, topical calcineurin inhibitors) or when those therapies are not advisable.

​Management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

​Elafibranor is anticipated to be approved by Health Canada for the treatment of
primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid
(UDCA) in adults with an inadequate response to UDCA, or as monotherapy in
adults unable to tolerate UDCA.

​For the treatment of moderate-to-severe atopic dermatitis (AD) in patients
aged 12 years and older who are candidates for systemic therapy.